On Thursday, March 26, 2020 at 7:00 p.m. ET, the University of Pennsylvania will announce admission decisions for Regular Decision applicants to the Class of 2024, the institution’s 268th class.
The admitted cohort of 3,404 was selected from a pool of 42,205 applicants. Penn enrolls a first-year class of 2,400 students across the College of Arts & Sciences, Penn Engineering, the Wharton School, and the School of Nursing.
Nationally, 50 states, Washington, D.C., Guam, Puerto Rico, and the US Virgin Islands are represented in the class with the highest concentration of admitted students from Pennsylvania, California, New York, New Jersey, Florida, and Texas. 168 students reside in the city of Philadelphia.
14% of the class are international students based on their citizenship, hailing from 98 countries from Albania to Zimbabwe.
53% of the admitted students are female, 53% are U.S. Citizens/Permanent Residents who self-identify as a member of a minority group, and 15% are first-generation college students. 13% of the admitted students had a parent or grandparent attend Penn in prior generations. 20% are estimated to qualify for a Federal Pell Grant.
Dean of Admissions Eric J. Furda C’87 commented, “Access and inclusion for talented students of all backgrounds continues to be one of the highest priorities of Penn’s President, Dr. Amy Gutmann. To have one in every five admitted students come from a Pell Grant-qualifying background is a testament to her leadership, particularly regarding Penn’s grant-based financial aid policies.”
Over 2,000 unique high schools are represented among this admitted class. Admitted students have pursued a most demanding secondary school curriculum within broad educational settings. Their middle 50% testing ranges are 1460-1560 on the SAT and 33-35 on the ACT.
As an institution, the University of Pennsylvania continues to respond to the changing environment related to coronavirus (COVID-19). See the University’s official response, and ongoing updates, here. For admissions updates related to COVID-19, please click here.